Eric N. Olson

Chairman-Molecular Biology Department at The University of Texas - Southwestern Medical Center

Eric N. Olson

Eric N. Olson

Chairman-Molecular Biology Department at The University of Texas - Southwestern Medical Center

Overview
Career Highlights

Exonics Therapeutics, Inc.
LoneStar Heart, Inc.
miRagen Therapeutics, Inc. (Inactive)

RelSci Relationships

4212

Number of Boards

9

Birthday

09/27/1955

Age

65

Relationships
RelSci Relationships are individuals Eric N. Olson likely has professional access to. A relationship does not necessarily indicate a personal connection.

Professor & Chairman-Molecular Genetics Department at The University of Texas - Southwestern Medical Center

Relationship likelihood: Strong

Co-Founder, Director at Miragen Therapeutics, Inc.

Relationship likelihood: Strong

Founder at Agios Pharmaceuticals, Inc.

Relationship likelihood: Strong

Director at Sloan-Kettering Institute For Cancer Research

Relationship likelihood: Strong

Co-Founder at Genetics Institute LLC

Relationship likelihood: Strong

Venture Advisor at 5AM Venture Management LLC

Relationship likelihood: Strong

Professor & Chair, Department of Pharmacology at University of Washington - School of Medicine

Relationship likelihood: Strong

Chairman, Department of Developmental Biology at The University of Texas - Southwestern Medical Center

Relationship likelihood: Strong

Vice Provost & Dean of Basic Research at The University of Texas - Southwestern Medical Center

Relationship likelihood: Strong

Co-Director at Columbia University - Center for Theoretical Neuroscience

Relationship likelihood: Strong

Paths to Eric N. Olson
Potential Connections via
Relationship Science
You
Eric N. Olson
Chairman-Molecular Biology Department at The University of Texas - Southwestern Medical Center
Education
Doctorate Degree

Wake Forest University is an institution of higher education dedicated to the pursuit of excellence in the liberal arts and in graduate and professional education. It operates Wake Forest College, a graduate school of arts and sciences, and four professional schools.

Memberships
Member
2000 - Current

The National Academy of Sciences (NAS) formed the Committee on International Security and Arms Control (CISAC) in 1980 as a permanent committee to bring the resources of the Academy to bear on critical problems of international security and arms control. CISAC, in the Policy and Global Affairs Division, draws from the nation’s finest scientific, technical, engineering and medical talent to advise the government, contribute to the work of non-governmental organizations, and inform the public about scientific and technical issues related to international security and arms control. CISAC’s work benefits from a rotating membership of distinguished scientists, policy and military experts. The Committee carries out its mandate through a variety of activities that receive financial support from public and private sponsors.

Member
Current

Founded in 1780, the American Academy of Arts and Sciences is an independent policy research center that conducts multidisciplinary studies of complex and emerging problems. The Academy’s elected members are leaders in the academic disciplines, the arts, business, and public affairs. With a current membership of 4,000 American Fellows and 600 Foreign Honorary Members, the Academy has four major goals: Promoting service and study through analysis of critical social and intellectual issues and the development of practical policy alternatives; Fostering public engagement and the exchange of ideas with meetings, conferences, and symposia bringing diverse perspectives to the examination of issues of common concern; Mentoring a new generation of scholars and thinkers through the Visiting Scholars Program and Hellman Fellowship Program; Honoring excellence by electing to membership men and women in a broad range of disciplines and professions. Click here to learn about our new members. The Academy's headquarters are in Cambridge, Massachusetts. With its geographically diverse membership, it conducts activities in this country and abroad

Member
Current

The National Academy of Medicine (NAM), formerly called the Institute of Medicine (IoM), is an American nonprofit, non-governmental organization. The National Academy of Medicine is a part of the National Academies of Sciences, Engineering, and Medicine, along with the National Academy of Sciences (NAS), National Academy of Engineering (NAE), and the National Research Council (NRC). The National Academy of Medicine provides national advice on issues relating to biomedical science, medicine, and health, and serves as an adviser to the nation to improve health. It aims to provide unbiased, evidence-based, and authoritative information and advice concerning health and science policy to policy-makers, professionals, leaders in every sector of society, and the public at large. Operating outside the framework of the U.S. federal government, it relies on a volunteer workforce of scientists and other experts, operating under a formal peer-review system. As a national academy, new members of the organization are elected annually by current members, based on their distinguished and continuing achievements in a relevant field as well as for their willingness to participate actively.

Career History
Co-Founder
2007 - Prior

miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO.

Co-Founder
1996 - 2000

Gilead Colorado, Inc. is a biopharmaceutical company that develops and markets drugs used for cardiovascular disorders. Their products include discovery of novel therapies and product identification and acquisition. The company was founded in 1996 and is headquartered in Westminster, CO.

Co-Founder
2010 - Prior

LoneStar Heart, Inc. develops cardiac restorative therapies for patients with heart failure. The firm functions in collaboration with the Texas Heart Institute, the University of Texas Southwestern Medical Center and a global network of leading clinicians. Its flagship product is Algisyl-LVR, a medical device under clinical development intended to prevent or reverse the progression of advanced heart failure in patients who have an enlarged left ventricle. The company was founded in June 2010 by James T. Willerson, Eric N. Olson and Olav B. Bergheim and is headquartered in Laguna Hills, CA.

Boards & Committees
Member, Scientific Advisory Board
Current

Hiberna Corp. provides organic drugs. The company was founded by Gordon van Dusen, Leslie Leinwand, Sandy Martin and Thomas G. Marr in 2006 and is headquartered in Boulder, CO.

Chairman, Scientific Advisory Board
Prior

Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma; and remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.

Chairman, Scientific Advisory Board
Prior

miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO.

Member, Medical Advisory Board
Current

The Howard Hughes Medical Institute (HHMI) is a nonprofit medical research organization that ranks as one of the nation’s largest philanthropies. HHMI plays a prominent role in advancing biomedical research and science education in the United States. Founded in 1953 by aviator and industrialist Howard R. Hughes, HHMI is headquartered in Chevy Chase, Maryland, and employs more than 3,000 individuals across the U.S. HHMI has an endowment of $16.1 billion of which the Institute spent $800 million for research and distributed $119 million in grant support for science education in fiscal year 2012

Member, Board of Scientific Counselors
Current

The Mount Desert Island Biological Laboratory is a non profit biomedical research institution. It helps to improve human health and well-being through basic research, education, and development ventures. The company was founded in 1898 and is headquartered in Bar Harbor, ME.

Member, Scientific Advisory Board
Current

Gladstone Institute of Cardiovascular Disease focuses on understanding how the entire cardiovascular network develops and functions, both in health and disease. They explore the cellular and molecular mecha- nisms underlying pluripotency and cardiogenesis, as well as the basic concepts in gene regulation, particularly those disrupted in human disease. They combine stem cell biology, gene editing techniques, and chemical biology approaches, while also engi - neering 3D tissues and organoids, and developing novel tech- nologies. Their goal is to fill existing gaps in cardiac regeneration and genetics and to find better therapeutic strategies for patients with cardiovascular disease.

Investments
Details Hidden

Exonics Therapeutics, Inc. develops therapies for neuromuscular diseases. It also develops gene editing technologies like CRISPR/Cas9 to permanently correct the majority of duchenne muscular dystrophy mutations. The company was founded by Eric N. Olson in February 2017 and is headquartered in Cambridge, MA.

Details Hidden

miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO.

Details Hidden

Gilead Colorado, Inc. is a biopharmaceutical company that develops and markets drugs used for cardiovascular disorders. Their products include discovery of novel therapies and product identification and acquisition. The company was founded in 1996 and is headquartered in Westminster, CO.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Eric N. Olson. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Eric N. Olson's profile does not indicate a business or promotional relationship of any kind between RelSci and Eric N. Olson.